Inicure lead compound characterised as a specific agonist for FPR1, which displays a biased signalling profile that leads to a functional selective activating of the human neutrophils class (https://doi.org/10.1002/JLB.2HI0520-317R).
Functional selective FPR1 signaling in favor of an activationof the neutrophil superoxide generating NOX2 complex
Pitching final at the AMR conference Basel
Presenting Inicure at the pitching final at the European AMR conference in Basel 25-26 February 2025 (at minute
GoWest 29-30 January
Looking forward to meet research partners and investors at the GoWest – Nordic capital forum 29-30 January.
New publication by Nationwide Childrens hospital in collaboration with Inicure
More about the publication